Primary systemic anaplastic large-cell lymphoma (CD30+): advances in biology and current therapeutic approaches.

@article{Fiorani2001PrimarySA,
  title={Primary systemic anaplastic large-cell lymphoma (CD30+): advances in biology and current therapeutic approaches.},
  author={Claudia Fiorani and Giovanna Vinci and Stefano Sacchi and Gloria Bonaccorsi and Tullio Artusi},
  journal={Clinical lymphoma},
  year={2001},
  volume={2 1},
  pages={29-37; discussion 38-9}
}
In 1985, Stein et al demonstrated the expression of the lymphoid activation antigen CD30/Ki by neoplastic cells. Fifteen years after the first description, anaplastic large-cell lymphomas (ALCL) are now thought to be a heterogeneous group in terms of their clinical, morphologic, phenotypic, cytogenetic, and molecular biology features. However, on the basis of a specific genetic anomaly and expression of a chimeric nucleophosmin anaplastic lymphoma kinase (NPM-ALK) protein and its variants, a… CONTINUE READING